NCT06533761
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06533761
Title Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Stelexis BioSciences
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | ESP


No variant requirements are available.